Brief: Helix Biopharma reports on advancement of its L-DOS47 phase I/II study in Poland
09/03/2016 01:18
March 8 (Reuters) - Helix Biopharma Corp HBP.TO : * Reports on advancement of its L-DOS47 phase I/II study in Poland * Registration office of medicinal products in Poland and bioethics committee approved an amendment to phase I/II study of L-DOS47 * Source text for Eikon urn:newsml:reuters.com:*:nCCN9WBvkD * Further company coverage HBP.TO ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020